

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Single Technology Appraisal (STA)

Rivaroxaban for the prevention of stroke in atrial fibrillation

Response to consultee and commentator comments on the provisional matrix of consultees and commentators

Version of matrix of consultees and commentators reviewed: Provisional matrix of consultees and commentators sent for consultation				
Summary of comments, action taken, and justification of action:				
	<i>Proposal:</i>	<i>Proposal made by:</i>	<i>Action taken:</i> Removed/Added/Not included/Noted	<i>Justification:</i>
	Add National Pharmacy Association	NICE Secretariat	Added	National Pharmacy Association meets the inclusion criteria and has a close interest in this appraisal topic therefore this organisation has been added to the matrix as a relevant general group commentator

	Add Grown up Congenital Heart Patients Association	NICE Secretariat		Added	Grown up Congenital Heart Patients Association meets the inclusion criteria and has a close interest in this appraisal topic therefore this organisation has been added to the matrix as a relevant patient / carer group consultee
	Remove Cardiac Risk in the Young (CRY)	NICE Secretariat		Removed	Cardiac Risk in the Young (CRY) meets the inclusion criteria but does not have a close interest in this appraisal topic therefore this organisation has been removed.
	Remove Cardiomyopath Association	NICE Secretariat		Removed	Cardiomyopath Association meets the inclusion criteria but does not have a close interest in this appraisal topic therefore this organisation has been removed.
	Remove HEART UK	NICE Secretariat		Removed	HEART UK meets the inclusion criteria but does not have a close interest in this appraisal topic therefore this organisation has been removed.